The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended the conversion of the conditional marketing authorisations of Comirnaty (BioNTech/Pfizer's vaccine) and Spikevax (Moderna's vaccine) against COVID-19 disease into regular marketing authorisations for which annual renewal will no longer be required. All other obligations for the companies remain in place.
Both vaccines were conditionally licensed at the time of their licensing. This imposed obligations on companies to report results from ongoing clinical trials and to provide additional data on the vaccines' pharmaceutical quality in the context of the planned increase in production.
These clinical trials and additional studies, including observational studies, have provided reassuring data on key aspects such as how well the vaccines prevent severe disease with COVID-19. In addition, companies have provided all requested additional data on the pharmaceutical quality of the vaccines.
Given all the available efficacy and safety data resulting from the high use of these vaccines, these obligations are no longer considered essential for the benefit-risk balance (of the products), which has paved the way for the transition from a conditional marketing authorisation to a regular marketing authorisation.
Conditional marketing authorisations are evaluated on an annual basis. The CHMP recommended conversion to regular marketing authorisations as a result of the second annual renewal process. This recommendation covers all existing and upcoming Comirnaty and Spikevax adapted vaccines, including the recently approved adapted Comirnaty Original/Omicron BA.1, Comirnaty Original/Omicron BA.4/5 and Spikevax bivalent Original/Omicron BA.1.
Like all medicines , Comirnaty and Spikevax continue to be closely monitored. The EMA will continue to evaluate any new data in a timely manner and will take action to protect patients as needed.
Notes
1. The conditional marketing authorisations were granted on the basis of (i) the positive risk-benefit balance, (ii) the fact that the vaccines addressed an unmet medical need and were to be used in the context of a public health emergency, and (iii) the likelihood that the applicants would be able to provide more complete clinical and qualitative data after authorisation, which had been deemed necessary taking into account the new mechanism of action of the vaccines and their very high expected use.
(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source